Annual SG&A
$239.80 M
+$103.12 M+75.45%
31 December 2022
Summary:
Mirati Therapeutics annual selling, general & administrative expenses is currently $239.80 million, with the most recent change of +$103.12 million (+75.45%) on 31 December 2022. During the last 3 years, it has risen by +$156.39 million (+187.49%).MRTX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$72.00 M
-$3.49 M-4.62%
30 September 2023
Summary:
Mirati Therapeutics quarterly selling, general & administrative expenses is currently $72.00 million, with the most recent change of -$3.49 million (-4.62%) on 30 September 2023.MRTX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$10.88 B
-$725.88 M-7.15%
30 September 2023
Summary:
Mirati Therapeutics TTM selling, general & administrative expenses is currently -$10.88 billion, with the most recent change of -$725.88 million (-7.15%) on 30 September 2023.MRTX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MRTX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +187.5% | +104.7% | -9283.7% |
| 5 y5 years | +1006.0% | +573.9% | -10000.0% |
MRTX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | at high | -4.6% | -3828.9% |
Mirati Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | $72.00 M(-4.6%) | $291.80 M(+4.0%) |
| June 2023 | - | $75.49 M(+2.7%) | $280.60 M(+8.2%) |
| Mar 2023 | - | $73.49 M(+3.8%) | $259.34 M(+8.1%) |
| Dec 2022 | $239.80 M(+75.4%) | $70.82 M(+16.5%) | $239.80 M(+12.8%) |
| Sept 2022 | - | $60.80 M(+12.1%) | $212.51 M(+13.7%) |
| June 2022 | - | $54.23 M(+0.5%) | $186.90 M(+15.2%) |
| Mar 2022 | - | $53.95 M(+23.9%) | $162.28 M(+18.7%) |
| Dec 2021 | $136.68 M(+63.9%) | $43.53 M(+23.7%) | $136.68 M(+15.4%) |
| Sept 2021 | - | $35.18 M(+18.8%) | $118.48 M(+14.4%) |
| June 2021 | - | $29.61 M(+4.4%) | $103.55 M(+10.5%) |
| Mar 2021 | - | $28.35 M(+11.9%) | $93.72 M(+12.4%) |
| Dec 2020 | $83.41 M(+95.9%) | $25.34 M(+25.1%) | $83.41 M(+18.6%) |
| Sept 2020 | - | $20.25 M(+2.4%) | $70.31 M(+15.7%) |
| June 2020 | - | $19.78 M(+9.6%) | $60.74 M(+19.4%) |
| Mar 2020 | - | $18.05 M(+47.5%) | $50.86 M(+19.5%) |
| Dec 2019 | $42.57 M(+96.4%) | $12.23 M(+14.5%) | $42.57 M(+16.0%) |
| Sept 2019 | - | $10.69 M(+8.0%) | $36.71 M(+17.1%) |
| June 2019 | - | $9.89 M(+1.4%) | $31.34 M(+19.2%) |
| Mar 2019 | - | $9.76 M(+53.2%) | $26.29 M(+21.3%) |
| Dec 2018 | $21.68 M(+61.2%) | $6.37 M(+20.0%) | $21.68 M(+18.5%) |
| Sept 2018 | - | $5.31 M(+9.8%) | $18.29 M(+13.6%) |
| June 2018 | - | $4.84 M(-6.1%) | $16.10 M(+8.0%) |
| Mar 2018 | - | $5.15 M(+72.7%) | $14.91 M(+10.9%) |
| Dec 2017 | $13.45 M(-12.0%) | $2.98 M(-4.3%) | $13.45 M(-6.4%) |
| Sept 2017 | - | $3.12 M(-14.6%) | $14.37 M(-2.4%) |
| June 2017 | - | $3.65 M(-1.1%) | $14.72 M(-0.9%) |
| Mar 2017 | - | $3.69 M(-5.3%) | $14.86 M(-2.9%) |
| Dec 2016 | $15.29 M(-2.9%) | $3.90 M(+12.3%) | $15.29 M(+2.2%) |
| Sept 2016 | - | $3.48 M(-8.2%) | $14.97 M(-4.4%) |
| June 2016 | - | $3.79 M(-8.3%) | $15.65 M(-2.8%) |
| Mar 2016 | - | $4.13 M(+15.5%) | $16.11 M(+2.2%) |
| Dec 2015 | $15.76 M(+24.1%) | $3.58 M(-14.1%) | $15.76 M(+1.3%) |
| Sept 2015 | - | $4.16 M(-1.9%) | $15.55 M(+3.3%) |
| June 2015 | - | $4.24 M(+12.2%) | $15.05 M(+9.1%) |
| Mar 2015 | - | $3.78 M(+12.3%) | $13.79 M(+8.6%) |
| Dec 2014 | $12.70 M | $3.37 M(-8.1%) | $12.70 M(+6.9%) |
| Sept 2014 | - | $3.66 M(+22.6%) | $11.87 M(-0.5%) |
| June 2014 | - | $2.99 M(+11.2%) | $11.93 M(+5.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | $2.69 M(+5.7%) | $11.32 M(+1.4%) |
| Dec 2013 | $11.18 M(+106.3%) | $2.54 M(-31.6%) | $11.16 M(+11.4%) |
| Sept 2013 | - | $3.72 M(+56.0%) | $10.02 M(+24.9%) |
| June 2013 | - | $2.38 M(-5.6%) | $8.02 M(+19.3%) |
| Mar 2013 | - | $2.52 M(+80.5%) | $6.72 M(+24.1%) |
| Dec 2012 | $5.42 M(+29.0%) | $1.40 M(-18.6%) | $5.42 M(+3.3%) |
| Sept 2012 | - | $1.72 M(+58.7%) | $5.24 M(+14.2%) |
| June 2012 | - | $1.08 M(-11.3%) | $4.59 M(-0.3%) |
| Mar 2012 | - | $1.22 M(-0.4%) | $4.61 M(+3.7%) |
| Dec 2011 | $4.20 M(-31.4%) | $1.23 M(+15.0%) | $4.44 M(+4.4%) |
| Sept 2011 | - | $1.06 M(-3.0%) | $4.26 M(-27.0%) |
| June 2011 | - | $1.10 M(+4.1%) | $5.83 M(-1.0%) |
| Mar 2011 | - | $1.05 M(+1.4%) | $5.89 M(-3.6%) |
| Dec 2010 | $6.12 M(+20.7%) | $1.04 M(-60.6%) | $6.11 M(-9.5%) |
| Sept 2010 | - | $2.64 M(+128.4%) | $6.76 M(+27.1%) |
| June 2010 | - | $1.16 M(-9.2%) | $5.31 M(+6.1%) |
| Mar 2010 | - | $1.27 M(-24.4%) | $5.01 M(+4.6%) |
| Dec 2009 | $5.07 M(-2.7%) | $1.68 M(+40.3%) | $4.79 M(+34.5%) |
| Sept 2009 | - | $1.20 M(+41.2%) | $3.56 M(-5.1%) |
| June 2009 | - | $850.20 K(-19.1%) | $3.75 M(-21.0%) |
| Mar 2009 | - | $1.05 M(+130.5%) | $4.75 M(-10.9%) |
| Dec 2008 | $5.21 M(+5.1%) | $456.00 K(-67.2%) | $5.33 M(-13.4%) |
| Sept 2008 | - | $1.39 M(-24.8%) | $6.15 M(+3.2%) |
| June 2008 | - | $1.85 M(+13.2%) | $5.96 M(+12.2%) |
| Mar 2008 | - | $1.63 M(+27.6%) | $5.31 M(+12.9%) |
| Dec 2007 | $4.96 M(+15.9%) | $1.28 M(+6.8%) | $4.70 M(+7.5%) |
| Sept 2007 | - | $1.20 M(-0.2%) | $4.37 M(+3.8%) |
| June 2007 | - | $1.20 M(+17.0%) | $4.22 M(+4.5%) |
| Mar 2007 | - | $1.03 M(+8.0%) | $4.03 M(-4.5%) |
| Dec 2006 | $4.28 M(+1.8%) | $950.20 K(-8.6%) | $4.22 M(-4.5%) |
| Sept 2006 | - | $1.04 M(+2.1%) | $4.42 M(+2.2%) |
| June 2006 | - | $1.02 M(-16.3%) | $4.33 M(-1.3%) |
| Mar 2006 | - | $1.22 M(+6.0%) | $4.38 M(+6.8%) |
| Dec 2005 | $4.20 M(+8.6%) | $1.15 M(+21.6%) | $4.10 M(+38.8%) |
| Sept 2005 | - | $944.20 K(-12.2%) | $2.96 M(+46.9%) |
| June 2005 | - | $1.08 M(+14.8%) | $2.01 M(+114.8%) |
| Mar 2005 | - | $936.80 K | $936.80 K |
| Dec 2004 | $3.87 M(+41.1%) | - | - |
| Dec 2003 | $2.74 M | - | - |
FAQ
- What is Mirati Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Mirati Therapeutics?
- What is Mirati Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Mirati Therapeutics?
- What is Mirati Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Mirati Therapeutics?
What is Mirati Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of MRTX is $239.80 M
What is the all time high annual SG&A for Mirati Therapeutics?
Mirati Therapeutics all-time high annual selling, general & administrative expenses is $239.80 M
What is Mirati Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of MRTX is $72.00 M
What is the all time high quarterly SG&A for Mirati Therapeutics?
Mirati Therapeutics all-time high quarterly selling, general & administrative expenses is $75.49 M
What is Mirati Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of MRTX is -$10.88 B
What is the all time high TTM SG&A for Mirati Therapeutics?
Mirati Therapeutics all-time high TTM selling, general & administrative expenses is $291.80 M